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Abstract
Introduction: Meropenem bactericidal activity depends on the time when the free drug concentrations remain
above the minimum inhibitory concentration of pathogens. The goal of this study was to compare clinical and
bacteriological efficacy of continuous meropenem infusion versus bolus administration in critically ill patients with
severe infection, and to evaluate the safety of both dosing regimens.
Methods: Patients admitted to the interdisciplinary Intensive Care Unit (ICU) who suffered from severe infections
and received meropenem were randomized either in the Infusion group (n = 120) or in the Bolus group (n = 120).
Patients in the Infusion group received a loading dose of 2 g of meropenem followed by a continuous infusion of
4 g of meropenem over 24 hours. Patients in the Bolus group were given 2 g of meropenem over 30 minutes
every 8 hours. Clinical and microbiological outcome, safety, meropenem-related length of ICU and hospital stay,
meropenem-related length of mechanical ventilation, duration of meropenem treatment, total dose of
meropenem, and ICU and in-hospital mortality were assessed.
Results: Clinical cure at the end of meropenem therapy was comparable between both groups (83.0% patients in
the Infusion vs. 75.0% patients in the Bolus group; P = 0.180). Microbiological success rate was higher in the
Infusion group as opposed to the Bolus group (90.6% vs. 78.4%; P = 0.020). Multivariate logistic regression
identified continuous administration of meropenem as an independent predictor of microbiological success (OR =
2.977; 95% CI = 1.050 to 8.443; P = 0.040). Meropenem-related ICU stay was shorter in the Infusion group
compared to the Bolus group (10 (7 to 14) days vs. 12 (7 to 19) days; P = 0.044) as well as shorter duration of
meropenem therapy (7 (6 to 8) days vs. 8 (7 to 10) days; P = 0.035) and lower total dose of meropenem (24 (21 to
32) grams vs. 48 (42 to 60) grams; P < 0.0001). No severe adverse events related to meropenem administration in
either group were observed.
Conclusions: Continuous infusion of meropenem is safe and, in comparison with higher intermittent dosage,
provides equal clinical outcome, generates superior bacteriological efficacy and offers encouraging alternative of
antimicrobial therapy in critically ill patients.
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Introduction
Severe infections in critically ill patients and increasing
antibiotic resistance are major healthcare problems affect-
ing morbidity and mortality in the intensive care unit.
Antibacterial drug discovery and development have slowed
considerably in recent years. The number of new antibac-
terial medicines entering the clinic has been declining and,
in view of this fact, new compounds for multi-drug resis-
tant Gram-negative bacilli will unlikely be available for
more than 10 years [1,2]. The problems associated with
escalating resistance and decreased development of anti-
biotics with novel mechanisms of action has required
more research into existing antibiotics. The effort to maxi-
mize antibiotic activity has led in recent years to the inter-
est for optimal dosing based on pharmacodynamic and
pharmacokinetic properties of antibiotics [3].
Because of broad spectrum activity against Gram-
negative and -positive organisms and low toxicity, mero-
penem remains a suitable choice for treatment of severe
infections in critically ill patients. It is currently estab-
lished that meropenem, like other b-lactam antibiotics,
displays time-dependent bactericidal activity and the
percentage of the dosing interval that free drug concen-
trations remain above the minimum inhibitory concen-
tration of pathogen (%fT > MIC) is the most important
parameter for predicting their antibacterial efficacy [4,5].
As a minimum standard for carbapenems the T > MIC
should be maintained at 40%, [6]. However, patients
with serious bacterial infections with T > MIC of 100%
displayed significantly greater clinical cure (82% vs. 33%;
P = 0.002) and bacteriological eradication (97% vs. 44%;
P < 0.001) than patients with T > MIC of < 100%, thus
maintaining antibiotic concentrations above the MIC for
100% of the dosing interval should be considered [7,8].
The maximum killing effect of b-lactams is reached at
four to five times the MIC with higher concentration
not contributing further to increasing the antimicrobial
effect. It can be presumed that intermittent infusion
recommended by pharmaceutical companies results in
high peak concentration and low through concentration
and can cause reduced efficacy. Furthermore, pathophy-
siological changes that occur in seriously ill patients
with sepsis often affect volume of distribution, drug
clearance and altered pharmacokinetic parameters mak-
ing these recommendations potentially inappropriate
[9-12]. The use of continuous administration of b-
lactams was studied in some trials [13-22], but strong
evidence of clinical efficacy of this alternative is lacking.
The goal of this study was to compare the clinical and
bacteriological efficacy of continuous infusion of mero-
penem versus traditional bolus administration in criti-
cally ill patients with severe infection, and to evaluate
the safety of both dosing regimens.
Materials and methods
This was a single-center, prospective, randomized, open-
label comparative study conducted at the interdisciplin-
ary ICU of Department of Anesthesiology and Intensive
Care Medicine at Charles University teaching hospital in
Plzen. The trial was approved by the local research
ethics committee (Ethics Committee of University Hos-
pital in Plzen). Informed consent was not required
because the protocol of meropenem administration was
considered the standard of the routine clinical practice
in this intensive care unit (ICU) and no interventions
were made during data collection and analysis. Never-
theless, subjects were informed at discharge that they
had participated in this clinical study and subsequent
written consent was obtained.
All patients admitted to the 11-bed interdisciplinary
ICU between September 2007 and May 2010 who suf-
fered, at admission or during the ICU stay, from severe
infection and received meropenem with predicted dura-
tion of treatment for at least four days were considered
for inclusion. All enrolled patients fulfilled the criteria
of sepsis [23]. Types of infections included abdominal,
respiratory, skin and soft tissue, bloodstream, central
nervous system (CNS), urinary tract or other sources of
infections. Diagnosis of infection was established in
accordance with predefined criteria [24]. Meropenem
administration was indicated mostly as second-line anti-
microbial therapy based on microbiological findings but
also as empirical therapy for sepsis without a proven
source and pathogen. Concomitant antimicrobial ther-
apy was allowed. The absolute majority of antimicrobial
therapy (meropenem and concomitant) was started
according to consultation and stewardship of a univer-
sity hospital microbiologist. The MIC of meropenem in
identified pathogens was determined by using E test (AB
BIODISK, Solna, Sweden) methodology.
Exclusion criteria included age younger than 18 years,
pregnancy, acute or chronic renal failure with glomeru-
lar filtration rate lower than 0.5 ml/s, immunodeficiency
or immunosuppressant medication, neutropenia (abso-
lute neutrophil count < 1,000 cells/mm3), and hypersen-
sitivity or allergy to meropenem. Glomerular filtration
rate (GFR) for all patients was daily calculated by using
of the four-variable Modification of Diet in Renal Dis-
ease (MDRD) formula [25]. For patients who developed
renal impairment (GFR < 0.5 ml/s) during the study, the
dosage of meropenem was adjusted according to pro-
duct labeling [26]. Antibiotic therapy was stopped at
improvement of the clinical state and signs of subsi-
dence of infection (body temperature below 38, 3°C for
more than 24 hours, white blood cells (WBC) count less
than 11,000/mm3 or decrease by 25% of maximal value)
[27,28].
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Patient’s randomization, protocol and outcome measures
Patients meeting inclusion criteria with no presence of
exclusion criteria were randomized using sealed opaque
envelopes in one-to-one proportion without stratification
to receive either continuous infusion (Infusion group, n =
120) or intermittent intravenous application (Bolus
group, n = 120) of open-label meropenem (Meronem;
AstraZeneca Pharmaceuticals, Macclesfield, Cheshire,
UK). The patients in the Infusion group received a load-
ing dose of 2 g of meropenem in 20 ml of normal saline
infused by central line over 30 minutes followed immedi-
ately by continuous infusion of 4 g of meropenem over
24 hours. With the respect to stability of meropenem, the
infusion was given as four 1 g infusions over six hours in
50 ml of normal saline [29,30]. The patients in the Bolus
group received 2 g of meropenem in 20 ml of normal sal-
ine infused by central line over 30 minutes every 8 hours.
In both groups, meropenem was administered through
separate lumen of central venous catheter using a perfu-
sor (Perfusor® fm (MFC); B. Braun, Melsungen AG,
Germany). Patients in both groups were treated during
their ICU stay by the regular team of ICU physicians and
received standard intensive care.
Primary outcome measures were clinical and microbio-
logical efficacy of meropenem therapy. In post-hoc suba-
nalyses, clinical and microbiological outcomes were
evaluated in subgroups of patients with empiric and cul-
ture-based therapy, in patients without concomitant ther-
apy potentially active against Gram-negative bacteria
(GNB), in patients with APACHE II > 20 and in patients
with MICs of pathogens higher or equal 1.5 mg/l. The
clinically evaluable population included patients who met
the protocol definition, received meropenem therapy for
at least four full days and had sufficient data available to
determine clinical outcome at the end of treatment
(EOT). Microbiologically evaluable patients had at least
one bacterial pathogen identified at baseline that was sus-
ceptible or intermediate to meropenem.
Clinical response was evaluated at the end of therapy as
treatment success or failure. Clinical success was defined
as complete or partial resolution of leukocytosis, tem-
perature, and clinical signs and symptoms of infection
(defined as cure or improvement). Failure consisted of
any of the following: persistence or progression of signs
and symptoms of infection, development of new clinical
findings consistent with active infection, or death from
infection. The addition of an agent for Gram-positive
bacteria coverage was not considered a clinical failure.
When a situation was unclear, two investigators indepen-
dently determined the status. If their initial assessments
differed, the third independent physician arbitrated the
result.
A microbiologist blinded to the patient allocation
assessed microbiological outcomes at the end of the
meropenem therapy. The categories of eradication and
presumed eradication were deemed as microbiological
success. Persistence, presumed persistence and resis-
tance were designated as microbiologic failure. For
patients with multiple organisms at the same infection
site, microbiologic evaluation was based on organisms
susceptible to meropenem. Detection of a new pathogen
from the site of infection during the meropenem ther-
apy was evaluated as colonization if no new antibiotic
therapy was indicated, or as superinfection if antibiotic
therapy to target the results of the new culture was
established. Patients who developed colonization were
classified as microbiological successes; patients with
superinfection caused by pathogens involved in thera-
peutic spectrum of meropenem were assessed as micro-
biological failures. Superinfections caused by methicillin-
resistant staphylococci (MRSA), Enterococcus faecium,
Candida spp. and other fungal species were not classi-
fied as microbiological failure. The decision between
colonization and superinfection was accomplished
according to the consultation between a microbiologist
and treating clinician. The outcome categories exact
definitions used are described in the additional file
(Additional file 1, Table S1).
Secondary outcome measures were meropenem-related
length of mechanical ventilation, meropenem-related
length of ICU and hospital stay (LOS), ICU and in-hospi-
tal mortality, duration of meropenem treatment, the total
dose of meropenem and the safety of both dosing regi-
mens. Meropenem-related length of mechanical ventila-
tion was defined as the number of days of mechanical
ventilation from the start of meropenem administration.
Meropenem-related length of stay was defined as the
number of days from the beginning of meropenem ther-
apy to the day of discharge from ICU or from the hospi-
tal. Safety of meropenem therapy was evaluated by
clinical symptoms (diarrhea, rash, vomiting and seizures)
during the meropenem therapy and by assessment of
laboratory parameters and their changes during merope-
nem therapy (transaminases, alkaline phosphatase, biliru-
bin, thrombocytes).
Other data, such as age, weight, gender, APACHE II
(Acute Physiology and Chronic Health Evaluation II)
and SOFA (Sequential Organ Failure Assessment) scores
at the start of meropenem therapy, diagnostic group,
type and etiology of infection treated by meropenem,
MICs of identified pathogens, length of ICU stay prior
to meropenem administration, occurrence and length of
previous antimicrobial therapy, number of antibiotics
given before the start of meropenem, the rate of empiric
and culture-based meropenem therapy and the rate of
community and nosocomial infection were recorded. C-
reactive protein (CRP), white blood cell (WBC) count,
platelet count, aspartate aminotransferase (AST), alanine
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aminotransferase (ALT), alkaline phosphatase (ALP) and
total bilirubin were examined at the start and at the end
of meropenem therapy.
Statistical analysis
Baseline demographic characteristics, safety and drug-
related adverse events, including laboratory results, were
assessed on an intention-to-treat (ITT) basis. The sec-
ondary clinical outcome measures were analyzed on
both, ITT and per protocol basis. The clinical cure rate,
concomitant antibiotic therapy, microbiological findings
and bacteriological success rate were evaluated only in
the per protocol population.
Sample size calculations were based on clinical success
rates in similar previous studies with continuous applica-
tion of meropenem and other b-lactam antibiotics present-
ing clinical and microbiological outcome improvement by
12% to 39% in the population [17,31,32]. We calculated a
study size of 95 patients in each group by postulating an
improvement of clinical outcome in a continuous group by
20% for two-sided tests with type I error of 5% and power
of 90%. Because of a predictable loss of 15% to 20% of
patients entering the study due to violation of protocol, we
proposed to increase the number of patients in each group
to 120. The Kolmogorov-Smirnov test was used to check
for normal distribution of data. Continuous normally dis-
tributed data were tested with paired or unpaired t test,
not normally distributed data using Mann-Whitney U test
and Wilcoxon signed-rank test. Categorical data were
tested using chi-square and Fisher’s exact test. Multiple
logistic regression with backward stepwise variable selec-
tion was used to identify the variables independently asso-
ciated with the clinical and microbiological outcome of
meropenem therapy in the clinically and microbiologically
evaluable patients. Factors with P < 0.20 according to uni-
variate analysis were entered into the multivariate model.
To evaluate model calibration, we performed the Leme-
show-Hosmer goodness-of-fit test. The predictive accuracy
of the multivariate model was expressed as the area under
the receiver operating characteristic (ROC) curve. Results
of logistic regression are reported as odds ratios (OR) with
95% confidence intervals (CI). Unless stated otherwise, nor-
mally distributed data are presented as mean ± standard
deviation, and as median (interquartile ranges) where not
normally distributed. Relative risk (RR) is presented with
95% CI. A P < 0.05 was considered statistically significant
for all tests. All calculations were performed with Med-
Calc® version 11.6.1.0. (Frank Schoonjans, MedCalc Soft-
ware, Broekstraat 52, 9030 Mariakerke, Belgium).
Results
A total of 299 patients were screened for eligibility dur-
ing the study period (Figure 1). Fifty-nine patients met
any of the exclusion criteria, 120 patients were
randomized to the Infusion group and 120 patients to
the Bolus group. Fourteen patients of the Infusion
group and 12 patients of the Bolus group were excluded
from the per protocol evaluation because of death or
other violation of protocol. Reasons for drop out in both
groups were similar. One hundred and six patients in
the Infusion group and 108 patients in the Bolus group
were found clinically evaluable. Because of the failure to
identify causative pathogen (negative cultures from the
presumed site of infection) in 10 patients from the Infu-
sion and in 6 patients from the Bolus group, only 96
patients in the Infusion group and 102 patients in the
Bolus group were selected for microbiological evaluation
(Figure 1).
Using ITT analysis both groups were well matched for
demographics and baseline characteristics. No significant
differences in severity of illness (APACHE II and SOFA
scores), in the type of infection and other evaluated
parameters were observed (Table 1), except for the
trend to a lower number of surgical patients (n = 18,
(15.0%) vs. n = 30, (25.0%); P = 0.075), and longer
length of ICU stay before the start of meropenem ther-
apy in the Infusion group (9.0 (5.0 to 16.0) days vs. 7.0
(3.0 to 11.0) days; P = 0.036).
The type, the rate and MICs of isolated pathogens in
clinically evaluable patients were similar (Table 2). The
dominant isolated pathogen in both groups was Kleb-
siella spp. (59.4% vs. 46.3%; P = 0.057).
Concomitant antibiotic therapy was used in more than
50% of clinically evaluable patients in the Infusion and
Bolus groups. There were no differences in the rate of
combined antimicrobial therapy and in the type of conco-
mitant antibiotics (Table 3). The group of penicillins
involved oxacillin, ampicillin and piperacillin/tazobactam,
aminoglycosides comprised gentamicin and amikacin,
fluorochinolons included ciprofloxacin and levofloxacin
and the antifungal drugs were represented by fluconazol,
voriconazole and amphotericin b. The concomitant anti-
biotic therapy potentially active against GNB was given in
11 patients in the Infusion group (3 - piperacillin/tazobac-
tam + gentamicin, 1 - piperacillin/tazobactam, 1 - amika-
cin, 5 - ciprofloxacin, 1- levofloxacin) and in 6 patients in
the bolus group (2-piperacillin/tazobactam, 1 - gentamicin
and 3 - ciprofloxacin; P = 0.314).
Linezolid or vancomycin for MRSA infection was indi-
cated in the Infusion group in seven patients (two
abdominal, three respiratory and two blood stream infec-
tion) and in five patients (two abdominal, one respiratory
and two blood stream infection) in the Bolus group (P =
0,768). Rate and indication of antimycotic therapy in
both groups was similar. Etiology of Candida spp. infec-
tion in the Infusion group was proven in 33 patients (16
abdominal, 13 respiratory and 4 urine infections) and in
30 patients (17 abdominal, 11 respiratory, 1 bloodstream
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and 1 urine infection) in the Bolus group (P = 0.654).
Aspergillus spp. etiology of respiratory infection was con-
firmed in one patient in the Infusion group.
The rate of clinical cure and improvement in clinically
evaluable patients at EOT (Table 4) was comparable
between the treatment groups (88 patients (83.0%) in
Moribund, life expectancy <4 days (n = 5)
Creatinine clearance <0.5 ml/sec (n = 33)
Randomized (n = 240)
Allocated to Infusion group 
(n = 120)
Allocated to Bolus group 
(n = 120)
Two patients died within four days (n = 2)
De-escalation, adjustment or termination 
of antimicrobial therapy (n = 10)
Transfer to other hospital (n = 2)
One patient died within four days (n = 1)
De-escalation, adjustment or termination 
of antimicrobial therapy (n = 11)
Clinically evaluable (n = 106) Clinically evaluable (n = 108)
Assessed for eligibility (n = 299)
Age <18 years   (n = 14)
Microbiologically evaluable (n = 96) Microbiologically evaluable (n = 102)
Immunosuppression (n = 7)
Pathogen not identified (n = 10) Pathogen not identified (n = 6)
Figure 1 Flow of participants through the trial.
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the Infusion group vs. 81 (75.0%) patients in the Bolus
group; P = 0.180; RR = 1.1069; 95% CI = 0.9634 to
1.2718). We did not observe any difference in other
evaluated subgroups of patients except for patients with
culture-based therapy, in which we found the trend for
better clinical outcome in the Infusion group (86.0%)
against the Bolus group (74.3%); (P = 0,051; RR =
1.1581; 95% CI = 1.007 to 1.3314). In patients with
intraabdominal infections a trend towards higher clinical
success rate was observed in the Infusion group (15
patients (83.3%) vs. 15 (55.6%); P = 0.063; RR = 1.500;
95% CI = 1.010 to 2.228) (Table 4). Shorter merope-
nem-related ICU stay was detected in both ITT and in
the clinically evaluable population in the Infusion com-
pared to the Bolus group (10 (7 to 14) days vs. 12 (7 to
19) days; P = 0.044) and (10 (7 to 16.5) days vs. 13 (8 to
21) days; P = 0.042), respectively (Table 5), but no dif-
ference was found in subgroups of patients with
APACHE II > 20 and patients with MICs of pathogen ≥
1.5 mg/l (Additional file 2, Table S2). The shorter dura-
tion of meropenem therapy (7 (6 to 8) days vs. 8 (7 to
10) days; P = 0.035) and lower total dose of meropenem
(24 (24 to 32) grams vs. 48 (42 to 60) grams; P <
0.0001) were observed in the Infusion group (Table 5).
The CRP concentration at the end of meropenem ther-
apy evaluated in post-hoc analysis was higher in the






Age (years) 44.9 ± 17.8 47.2 ± 16.3 0.503
Male 78 (65.0%) 83 (69.2%) 0.583
Weight (kg) 78 (70.0 to 90.0) 80 (72.0 to 95.5) 0.079
APACHE II 21.4 ± 7.9 22.1 ± 8.79 0.545
SOFA 10.4 ± 2.9 10.6 ± 3.5 0.738
GFR calculated by MDRD (ml/s) 1.20 (0.77 to 1.80) 1.19 (0.88 to 1.59) 0.813
Diagnostic group n (%)
Cardiac surgery 4 (3.3%) 2 (1.7%) 0.685
Neurology and neurosurgery 3 (2.5%) 3 (2.5%) 1,000
Surgery 18 (15.0%) 30 (25.0%) 0.075
Gastroenterology 22 (18.3%) 14 (11.7%) 0.205
Traumatology 43 (35.8%) 45 (37.5%) 0.788
Respiratory failure 2 (1.7%) 7 (5.8%) 0.171
Circulatory failure 24 (20.0%) 18 (15.0%) 0.396
Other 4 (3.3%) 1 (0.8%) 0.370
Type of infection n (%)
Not identified 0 (0.0%) 2 (1.6%) 0.498
Abdominal 23 (19.2%) 31 (25.8%) 0.357
Respiratory 66 (55.0%) 61 (50.8%) 0.605
Soft tissues, skin 5 (4.2%) 6 (5.0%) 1.000
Bloodstream 10 (8.3%) 11 (9.2%) 1.000
Uroinfection 11 (9.2%) 6 (5.0%) 0.314
Central nervous system 3 (2.5%) 2 (1.6%) 1.000
More sources 2 (1.6%) 1 (0.8%) 1.000
Nosocomial infection 110 (91.7%) 113 (94.2%) 0,616
Concomitant ATB therapy n (%) 58 (48.3%) 61 (50.8%) 0.796
Concomitant ATB therapy potentially active against GNB 11 (9.2%) 6 (5.0%) 0.314
Previous ATB therapy n (%) 114 (95.0%) 113 (94.2%) 1.000
Previous ATB therapy (days) 7.0 (6.0 to 8.0) 7.0 (6.0 to 8.0) 0.338
Number of previous ATB 3 (3 to 5) 4 (3 to 5) 0.509
Empiric therapy n (%) 6 (5.0%) 7 (5.8%) 1.000
Length of ICU stay before meropenem therapy (days) 9.0 (5.0 to 16.0) 7.0 (3.0 to 11.0) 0.036
Leucocytes (x 109/L) 15.9 (11.5 to 21.1) 14.1 (11.2 to 19.6) 0.437
CRP (mg/L) 155 (115 to 197) 199 (117 to 262) 0.090
Values are presented as absolute (percentage) or mean ± standard deviation or median (interquartile range). APACHE II, Acute Physiology and Chronic Health
Evaluation II; ATB, antibiotic; CRP, C-reactive protein; GFR, Glomerular filtration rate; GNB, Gram-negative bacteria; ICU, intensive care unit; MDRD, Modification of
Diet in Renal Disease; SOFA, Sequential Organ Failure Assessment.
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Bolus group in overall clinically evaluable patients (59
(32 to 87) mg/l vs. 72 (37 to 114) mg/l; P = 0.037) and
in the subgroup of patients with APACHE II > 20 (62
(32 to 87) mg/l vs. 78 (42 to 126) mg/l; P = 0,036)
(Additional file 2, Table S2).
Microbiological success rate (assessed in microbiologi-
cally evaluable patients only) was higher in the Infusion
group (87 patients with overall pathogen eradication
(90.6%) vs. 80 (78.4%); P = 0.020; RR = 1.156; 95% CI =
1.024 to 1.303). In the subanalyses we detected similar
results in subgroups of patients with culture-based ther-
apy and in patients without concomitant antibiotic ther-
apy potentially active against GNB (Table 6.).
In single pathogens, we observed a trend to better effi-
cacy of infusion of meropenem in infections with Kleb-
siella spp. etiology (58 eradications (92.1%) vs. 39 (78.0%);
P = 0.055; RR = 1.180; 95% CI = 1.002 to 1.391) (Table 6).
Similar results in the rate of overall persistence and resis-
tance were found with no differences in single pathogens
(Table 6). The rate of colonization and superinfection dur-
ing meropenem therapy did not differ (Additional file 3,
Table S3). None of the isolates of meropenem therapeutic
spectrum cultured from the site of infection during mero-
penem therapy required the initiation of new antibiotic
therapy at EOT and all of these findings were classified as
colonization. Superinfections with fungal species etiology
necessitated antimycotic therapy but according to protocol
were not evaluated as microbiological failure.
In multivariate logistic analysis, the number of antibio-
tics given before the start of meropenem (OR = 0.478;
95% CI = 0.323 to 0,706; P = 0.0002) and the age (OR =
0.947; 95% CI = 0.917 to 0.973; P = 0.0001) were nega-
tively associated with clinical success of meropenem
therapy. Continuous administration of meropenem was
independently related to the microbiological success
(OR = 2.977; 95% CI = 1.050 to 8.443; P = 0.040). Pre-
dictors of microbiological failure were the abdominal
infection (OR = 0.249; 95% CI = 0.092 to 0,674; P =
0.006) and the number of antibiotics given before the
start of meropenem (OR = 0.581; 95% CI = 0.383 to
0.881; P = 0.011). The performance of the final multi-
variate logistic models for clinical and microbiological
outcome was good (Lemeshow-Hosmer goodness-of fit
test for clinical and microbiological outcome with P =
0.63 and P = 0.53, respectively), and discriminated rea-
sonably well between success and failure of meropenem
therapy. The area under the ROC curve for clinical and
microbiological outcome was 0.80, and 0.78, correctly
predicting clinical and microbiological outcome (82.97%
and 85.3%, respectively).
Possible meropenem-related clinical adverse events
were rare and the rate in both groups did not differ
(Additional file 4, Table S4). In laboratory parameters
related to the safety of meropenem, we observed no dif-
ference between groups, although there was considerable
Table 2 Bacterial isolates and susceptibility characteristics to meropenem in clinically evaluable population










None cultured 10 (9.4%) 6 (5.6%) 0.310 n/a n/a n/a
Acinetobacter spp. 8 (7.5%) 12 (11.1%) 0.482 2.000 (1.000 to 2.000) 1.500 (1.500 to 2.000) 0.635
Citrobacter spp. 3 (2.8%) 4 (3.7%) 1.000 0.190 (0.092 to 0.422) 0.125 (0.040 to 0.470) 0.724
Enterobacter spp. 3 (2.8%) 7 (6.5%) 0.332 0.190 (0.093 to 0.331) 0.060 (0.053 to 0.090) 0.170
Escherichia coli 6 (5.7%) 9 (8.3%) 0.594 0.090 (0.090 to 0.120) 0.120 (0.072 to 0.380) 0.260
Klebsiella spp. 63 (59.4%) 50 (46.3%) 0.057 0.120 (0.090 to 0.130) 0.090 (0.060 to 0.130) 0.205
Morganella morganii 3 (2.8%) 5 (4.6%) 0.721 0.250 (0.250 to 0.542) 0.320 (0.250 to 0.535) 0.760
Pseudomonas aeruginosa 4 (3.8%) 6 (5.6%) 0.748 2.000 (1.750 to 2.000) 1.750 (1.000 to 2.000) 0.363
Serratia marcescens 4 (3.8%) 6 (5.6%) 0.748 0.110 (0.094 to 0.222) 0.125 (0.094 to 0.190) 0.830
Stenotrophomonas maltophilia 2 (1.9%) 3 (2.8%) 1,000 2.000 (2.000 to 2.000) 2.000 (1.625 to 2.000) 0.519
MIC of all microorganisms 0.125 (0.090 to 0.640) 0.130 (0.090 to 0,350) 0.970
Values are presented as absolute (percentage) or median (interquartile range).
1 Isolates do not include all pathogens, but those treated with meropenem; MIC, minimum inhibitory concentration; n/a, not applicable







Any 51 (48.1%) 55 (50.9%) 0.685
Penicillins 11 (10.4%) 5 (4.6%) 0.126
penicillin G 3 1 0.367
oxacillin 4 2 0.443
piperacillin/tazobactam 4 2 0.443
Aminoglycosides 4 (3.8%) 1 (0.9%) 0.210
Fluoroquinolones 6 (5.7%) 3 (2.8%) 0.330
Vancomycin 4 (3.8%) 11 (10.2%) 0.106
Linezolid 11 (10.4%) 7 (6.5%) 0.335
Metronidazole 7 (6.6%) 13 (12.0%) 0.240
Antifungals 34 (32.1%) 30 (27.6%) 0.551
Values are presented as absolute (percentage).
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increase in concentration of ALP at EOT in both groups
against the baseline. The platelet count rose in the Bolus
group significantly (Additional file 5, Table S5).
Discussion
In our study, continuous infusion of four grams of mer-
openem per day preserved a similar rate of clinical cure,
Table 4 Clinical cure rates in clinically evaluable patients at the end of treatment.
Infusion, n (%) Bolus, n (%) P-value
Overall 88/106 (83.0%) 81/108 (75.0%) 0.180
Cured 30/106 (28.3%) 24/108 (21.3%) 0.347
Improved 58/106 (54.7%) 57/108 (52.8%) 0.786
Culture-based therapy 86/100 (86.0%) 75/101 (74.3%) 0.051
Empiric therapy 4/6 (66.7%) 6/7 (85.7%) 0.560
Without concomitant ATB therapy potentially active against GNB 80/95 (84.2%) 76/102 (74.5%) 0.114
APACHE II > 20 37/49 (75.5%) 42/53 (79.2%) 0.813
MIC ≥ 1.5 mg/l 10/14 (71.4%) 12/21 (57.1%) 0.488
Type of infection
Not identified 0 1/1 (100%) 1.000
Abdominal 15/18 (83.3%) 15/27 (55.6%) 0.063
Respiratory 52/58 (89.7%) 47/56 (83.9%) 0.416
Soft tissues, skin 4/5 (80.0%) 3/4 (75.0%) 1.000
Bloodstream 7/9 (77.8%) 8/11 (72.7%) 1.000
Urinary tract 7/11 (63.6%) 5/6 (83.3%) 0.600
CNS 3/3 (100%) 2/2 (100%) n/a
More sources 2/2 (100%) 1/1 (100%) n/a
Values are presented as absolute (percentage). APACHE II, Acute Physiology and Chronic Health Evaluation II; ATB, antibiotic; CNS, central nervous system; GNB,
Gram-negative bacteria; MIC, minimum inhibitory concentration; n/a, not applicable
Table 5 Outcome in ITT and clinically evaluable patients
Parameter Infusion Bolus P-value
Number of patients
ITT 120 120
Clinically evaluable 106 108
Meropenem-related length of mechanical ventilation
ITT 9 (5 to 13) 11 (6 to 17) 0.051
Clinically evaluable 9 (5 to 15) 12 (6 to 19) 0.058
Meropenem-related ICU LOS
ITT 10 (7 to 14) 12 (7 to 19) 0.044
Clinically evaluable 10 (7 to 16.5) 13 (8 to 21) 0.042
Meropenem-related hospital LOS
ITT 26 (17 to 38) 22 (12 to 35) 0.079
Clinically evaluable 28 (18 to 39) 25 (14 to 42) 0.412
ICU mortality
ITT 18 (15.0%) 25 (20.8%) 0.313
Clinically evaluable 14 (11.6%) 17 (14.2%) 0.701
Hospital mortality
ITT 21 (17.5%) 28 (23.3%) 0.337
Clinically evaluable 17 (16.0%) 19 (15.7%) 0.857
Duration of meropenem therapy (days)
ITT 7 (5 to 8) 8 (6 to 9) 0.041
Clinically evaluable 7 (6 to 8) 8 (7 to 10) 0.035
Total dose of meropenem (g)
ITT 24 (21 to 32) 48 (42 to 48) < 0.0001
Clinically evaluable 24 (24 to 32) 48 (42 to 60) < 0.0001
Values are presented as absolute (percentage) or median (interquartile range). ICU, intensive care unit; ITT, intention-to-treat; LOS, length of stay
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but reached a higher antimicrobial efficacy compared to
intermittent bolus administration of six grams of mero-
penem divided in three doses. Multiple logistic regres-
sion identified the infusion of meropenem as an
independent predictor of microbiological success. As far
as we know, our study provides the largest patient-data
pool concerning the issue of dosing regimens of mero-
penem and their microbiological and clinical efficacy in
the critically ill. Kojika et al. [33], compared prolonged
and bolus administration of meropenem in 10 patients
with abdominal sepsis (5 in each group). Apart from
early improvement of systemic inflammatory reactive
syndrome (SIRS) score, no changes in body temperature,
white blood cell count and serum CRP were demon-
strated. In a retrospective cohort study in patients with
ventilator associated pneumonia (VAP), Lorente et al.
[17] observed significant clinical improvement in the
infusion group (90.5% vs. 59.6%; P < 0.001). Intermittent
application of 1 g of meropenem every six hours in this
study might not reach required effective T > MIC and
contribute to worse clinical outcome. Nicasio et al. [34]
in a prospective, observational evaluation with a histori-
cal control group in patients with VAP presented
reduced infection-related mortality (8.5% vs. 21.6%; P =
0.029), infection-related length of stay (11.7 ± 8.1 vs
26.1 ± 18.5; P = 0.001), and fewer events of superinfec-
tion (16% vs. 35.1%; P = 0.007) in patients treated by
administration of three-hour infusions of cefepime 2 g
every eight hours or meropenem 2 g every eight hours
plus tobramycin and vancomycin. The retrospective
and/or historical control design of these encouraging
studies strongly affects their power.
Alas, our study failed to prove the primary outcome
hypothesis of better clinical cure in the Infusion group
(83% vs. 75%; P = 0.180). We have observed only a
trend towards better clinical outcome in patients with
abdominal infection (83.3% vs. 55.6%; P = 0.063). Some
factors could contribute to these negative results. First,
our sample size calculation was based on previously
published results (Grant 2002, Lorente 2007), but these
seem to be overly optimistic. Second, more than half of
evaluated groups comprised post-surgery or trauma
Table 6 Microbiological success rates in microbiologically evaluable patients
Infusion group, n (%) Bolus group, n (%) P-value
Eradication overall 87/96 (90.6%) 80/102 (78.4%) 0.020
Verified eradication 67/96 (69.8%) 62/102 (60.8%) 0.233
Presumed eradication 20/96 (20.8%) 18/102 (17.6%) 0.592
Culture-based therapy 82/90 (91.1%) 74/95 (77.9%) 0.015
Empiric therapy 5/6 (83.0%) 5/7 (71.4%) 1.000
Without concomitant ATB therapy potentially active against GNB 77/85 (90.6%) 75 (78.1%) 0.026
APACHE II > 20 41/47 (87.2%) 36/49 (73.5%) 0.125
MIC ≥ 1.5 mg/l 11/14 (78.6%) 13/21 (61.9%) 0.292
Acinetobacter spp. 7/8 (87.5%) 9/12 (75%) 0.619
Citrobacter spp. 3/3 (100%) 3/4 (75%) 1.000
Enterobacter spp. 3/3 (100%) 7/7 (100%) n/a
Escherichia coli 5/6 (83.3%) 7/9 (77.7%) 1.000
Klebsiella spp. 58/63 (92.1%) 39/50 (78.0%) 0.055
Morganella morganii 3/3 (100%) 5/5 (100%) n/a
Pseudomonas aeruginosa 3/4 (75%) 3/6 (50%) 0.571
Serratia marcescens 4/4 (100%) 6/6 (100%) n/a
Stenotrophomonas maltophilia 1/2 (50%) 1/3 (33.3%) 1.000
Persistence overall 9/96 (9.4%) 22/102 (21.6%) 0.020
Acinetobacter spp. 0/8 (0%) 2/12 (16.7%) 0,495
Citrobacter spp. 0/3 (0%) 1/4 (25.0%) 1.000
Escherichia coli 1/6 (16.7%) 2/9 (22.2%) 1.000
Klebsiella spp. 5/63 (7.9%) 11/50 (22.0%) 0.055
Pseudomonas aeruginosa 0/4 (0%) 2/6 (33.3%) 0.491
Stenotrophomonas maltophilia 1/2 (50.0%) 0/3 (0%) 0.400
Resistance 2/96 (2.1%) 4/102 (3.9%) 0.684
Acinetobacter spp. 1/8 (12.5%) 1/12 (8.3%) 1.000
Pseudomonas aeruginosa 1/4 (25.0%) 1/6 (16.7%) 1.000
Stenotrophomonas maltophilia 0/2 (0%) 2/6 (33.3%) 1.000
Values are presented as absolute (percentage). APACHE II, Acute Physiology and Chronic Health Evaluation II; ATB, antibiotic; GNB, Gram-negative bacteria;
MIC, minimum inhibitory concentration
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patients and other factors could play a role in their out-
come. Nevertheless, the major cause of the failure to
prove better clinical outcome in the Infusion group con-
sists probably in the disproportion of daily cumulative
dose of meropenem between groups (four grams in the
Infusion and six grams in the Bolus group) and little dif-
ference between both types of meropenem administra-
tion in achieving T > MIC in relatively susceptible
pathogens. We calculated the dose of meropenem (2 g
every eight hours) in the Bolus group according to the
suggestion for achievement antibiotic’s optimal PTA
(probability of target attainment) and CFR (cumulative
fraction of response) in critically ill patients with serious
infections [10,35-39], but the MICs in greater part of
isolated pathogens (84.3%) were very low, which pro-
longed the effective time in the intermittent dosing regi-
men. Only in 15.7% of pathogens (Acinetobacter spp.,
Pseudomonas aeruginosa and Stenotrophomonas malto-
philia) were MICs higher (2.000 (1.500 to 2.000) mg/l)
(Table 2). Although there was no difference in overall
clinical outcome, some laboratory markers of infection
stress could indicate better efficacy of continuous treat-
ment. Despite similar values of WBC and CRP at the
start of therapy, the CRP levels at EOT were lower in
the Infusion group (P = 0.037) (Additional file 2, Table
S2).
Notwithstanding the same clinical outcome, we
observed the trend towards shorter meropenem-related
length of mechanical ventilation and significant shorter
meropenem-related length of ICU stay in the Infusion
group (Table 5). Similar results in comparable b-lactams
studies demonstrated Nicasio et al. 2010 (shorter infec-
tion-related stay), Lodise et al. 2007 and Merchant et al.
2008 (both shorter hospital stay) [34,40,41]. We did not
find a difference in hospital LOS; however, the results in
both groups were confounded by prolonged hospitaliza-
tion of several patients with severe critical illness poly-
neuromyopathy and other complications in consequence
of severe multiple organ failure. Hospital and ICU mor-
tality in the Infusion group in ITT and in the clinically
evaluable population was somewhat lower but not sig-
nificantly, contrary to results of some nonrandomized
studies [34,40,42].
Continuous administration of meropenem was asso-
ciated with improvement of bacteriological efficacy docu-
mented as higher eradication rate and lower bacterial
persistence (Table 6). A possible explanation for better
microbial clearance in the infusion group could be the
maldistribution of blood flow in the microcirculation in
critically ill patients. Continuous application of merope-
nem can probably maintain higher concentrations of mer-
openem in the tissues than intermittent bolus dosing [43].
To date, no study comparing microbiological outcome
of both dosing regimens of meropenem has been
published. Two studies showed an improved bacteriolo-
gical efficacy of continuous application of beta-lactams
(ceftriaxone [44] and piperacillin/tazobactam [31], but
also conflicting results were published [45-47].
No difference between both groups was observed in the
rate of resistance, colonization and superinfection in our
study (Additional file 3, Table S3). The occurrence of
resistance in infusion and bolus group was low (2.1% vs.
3.9%) and developed in typical pathogens with lower sus-
ceptibility to meropenem (Acinetobacter spp., Pseudomo-
nas aeruginosa, Stenotrophomonas maltophilia) (Table 6).
The representation of antibiotics given as concomitant
therapy in both groups was similar. The high rate of
concomitant antifungal drugs (32.1% in the Infusion and
27.6% in the Bolus group) was undoubtedly associated
with previous antibiotic therapy (95% in the Infusion
and 94.2% in the Bolus group) and related to preceding
ICU stay prior to meropenem therapy was commenced.
The most commonly reported drug-related adverse
events in patients treated with meropenem include diar-
rhea, rash, seizures and/or nausea and vomiting [29,48].
We did not evaluate the nausea, because all randomized
patients in our study were sedated and mechanically
ventilated. Meropenem administration was generally
well tolerated and the incidence and types of adverse
events possibly related to meropenem were similar in
both treatment groups (Additional file 4, Table S4). The
overall rate of adverse events was not frequent (9.2%),
their relevance was relatively low and in none of the
patients was meropenem therapy interrupted due to
adverse effects. The most frequent events were diarrhea
and vomiting (4.2% in the Infusion group vs. 5.8% in the
Bolus group and 1.7% vs. 2.5%, respectively); however,
the association with meropenem administration was
dubious and all events occurred in the period of conver-
sion from parenteral to enteral nutrition. None of the
diarrhea events was associated with Clostridium difficile
infection. The only case of seizures was observed in a
patient with traumatic brain injury and ceased immedi-
ately after anticonvulsive therapy was established. None
of the four episodes of rash were clinically significant
and resolved spontaneously. Increased levels of ALT,
AST, ALP, bilirubin and thrombocytosis are the most
frequently reported laboratory adverse events related to
meropenem administration [29,48]. We have observed a
significant increase of platelet count in the Bolus group
and the rise of ALP in both groups (Additional file 5,
Table S5). We found no intergroup difference and no
therapeutic measures were necessary. The tolerability
profile of meropenem is well established, and the safety
of the drug has been extensively reviewed [48,49]; how-
ever, to our knowledge, no studies have formally exam-
ined and compared adverse effects of continuous or
bolus regimens of meropenem.
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Our study has several limitations that should be taken
into account when interpreting the results. It was not
blinded, and was conducted in only one center. The
influence of bias in clinical evaluation, despite the third
person being involved in case of ambiguity, is indisputa-
ble. On the contrary, knowing about this risk of bias, the
evaluation of clinical success in the Infusion group could
be more strict and censorious. This could explain the dis-
crepancy between insignificant clinical and positive bac-
teriological results, especially in view of the fact that a
microbiologist blinded to the patients’ allocation group
performed microbiological assessment. Another limita-
tion is frequent concomitant antibiotic therapy (48.1% in
the Infusion and 50.9% in the Bolus group) reducing the
validity of conclusions about the only impact of merope-
nem. The dose of meropenem in the Bolus group (6 g/
24 hrs) might be potentially confounding, despite that it
was used in accordance with the recommendations for
the critically ill patients [10,35-39]. Using this dose, the
concentration of meropenem could reach T > MIC for
100% of dosing interval in the susceptible pathogens with
relatively low MIC. This may potentially favor the Bolus
group patients and mask the pharmacodynamic benefit
of a continuous regimen. In view of this fact, we recom-
mend for the next studies the use of the same dose of
meropenem in both arms adjusted according to the
detected MIC. We did not monitor time between the
onset of sepsis and administration of antibiotic therapy,
which is an important variable correlating with the out-
come. Nevertheless, the patients of both groups were
treated by the stable team in one ICU, so we could pre-
sume that there were no substantial differences between
both groups in periods between the onset of sepsis and
the start of therapy. We observed shorter meropenem-
related ICU LOS in infusion group; however, the ICU
discharge criteria were not predefined, which further lim-
its interpretation of our results.
Conclusions
Continuous infusion of meropenem is safe in compari-
son with a higher bolus dose, provides equal clinical
outcome, generates superior bacteriological efficacy and
offers the encouraging alternative of antimicrobial ther-
apy in critically ill patients.
Continuous administration of meropenem was inde-
pendently associated with favorable microbiological out-
come, was connected with shorter length of ICU stay
and with fewer days of meropenem therapy.
The reason for failure to demonstrate better clinical
cure in the infusion group in spite of the advantageous
pharmacodynamic attributes we see in little difference
between both types of meropenem administration in
achieving T > MIC in relatively susceptible pathogens.
The efficacy of continuous or prolonged infusion of
meropenem should be investigated in randomized, con-
trolled trials with equal daily doses in both regimens
and in populations suffering from infections caused by
multi-drug resistant GNB with elevated MICs.
Key messages
• Continuous infusion of meropenem is safe, in
comparison with higher bolus dose, provides equal
clinical outcome, generates superior bacteriological
efficacy and offers encouraging alternatives of anti-
microbial therapy in critically ill patients.
• In this study, continuous administration of mero-
penem was identified as an independent predictor of
microbiological success and was associated with
shorter length of ICU stay and with fewer days of
meropenem therapy.
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